Verition Fund Management
GRCL

Verition Fund Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Verition Fund Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-86,644
Closed -$250K – 2776
2023
Q3 		$250K Buy
+86,644
New +$317K ﹤0.01% 1845

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Verition Fund Management's GRCL Position: Q4 2023 in Review

Verition Fund Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2023, closing a stake of 86,644 shares — an estimated $250K sold.

Verition Fund Management first reported a position in GRCL in Q3 2023 and held it in 1 quarter. The position peaked at $250K in Q3 2023. 63 funds tracked by Wall St. Rank hold GRCL as of Q4 2023.

  • Verition Fund Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 86,644 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2023, an estimated $250K.
  • Verition Fund Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023 and held it in 1 quarter.
  • Verition Fund Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $250K in Q3 2023.
  • 63 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.